250 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
ALKS Alkermes plc $38.61 $6B N/A
Article Searches
Should Value Investors Pick Alaska Air Group (ALK) Now? http://www.zacks.com/stock/news/432246/should-value-investors-pick-alaska-air-group-alk-now?cid=CS-ZC-FT-432246 Jun 20, 2019 - Let's see if Alaska Air Group (ALK) stock is a good choice for value-oriented investors right now from multiple angles.
Airline Stock Roundup: LUV's 737 MAX Update, ALK & JBLU's Bullish Q2 Views http://www.zacks.com/stock/news/431158/airline-stock-roundup-luvs-737-max-update-alk-jblus-bullish-q2-views?cid=CS-ZC-FT-431158 Jun 18, 2019 - Bullish unit revenue projections for the second quarter of 2019 from Alaska Air (ALK) and JetBlue (JBLU) highlight the upbeat demand for air travel.
Alaska Air Group (ALK) May Load Factor Up, Q2 View Upbeat http://www.zacks.com/stock/news/429531/alaska-air-group-alk-may-load-factor-up-q2-view-upbeat?cid=CS-ZC-FT-429531 Jun 14, 2019 - With traffic growth exceeding capacity expansion, Alaska Air Group's (ALK) May load factor rises. Additionally, the company alters its Q2 view for unit revenues, non-fuel unit costs and fuel costs.
Alkermes Initiates Monothearpy Expansion Phase of ALKS 4230 http://www.zacks.com/stock/news/429125/alkermes-initiates-monothearpy-expansion-phase-of-alks-4230?cid=CS-ZC-FT-429125 Jun 13, 2019 - Alkermes (ALKS) initiates monotherapy expansion phase of ALKS 4230 to treat patients with renal cell carcinoma or melanoma.
Alkermes advancing ALKS 4230 in kidney cancer and melanoma https://seekingalpha.com/news/3470695-alkermes-advancing-alks-4230-kidney-cancer-melanoma?source=feed_news_all Jun 12, 2019 - Alkermes plc (NASDAQ:ALKS) has initiated the monotherapy expansion stage of its Phase 1/2 ARTISTRY-1 trial evaluating ALKS 4230 in patients with renal cell carcinoma or melanoma. This portion of the s
CBM vs. ALKS: Which Stock Should Value Investors Buy Now? http://www.zacks.com/stock/news/425612/cbm-vs-alks-which-stock-should-value-investors-buy-now?cid=CS-ZC-FT-425612 Jun 06, 2019 - CBM vs. ALKS: Which Stock Is the Better Value Option?
Biogen Reports Interim Phase III Data on Diroximel Fumarate http://www.zacks.com/stock/news/422832/biogen-reports-interim-phase-iii-data-on-diroximel-fumarate?cid=CS-ZC-FT-422832 May 31, 2019 - Biogen (BIIB) announces new interim results from phase III EVOLVE-MS-1 study, which showed that the diroximel fumarate was generally well tolerated in people with relapsing MS.
Allergan's (AGN) Vraylar Gets FDA Nod for Bipolar Depression http://www.zacks.com/stock/news/421714/allergans-agn-vraylar-gets-fda-nod-for-bipolar-depression?cid=CS-ZC-FT-421714 May 29, 2019 - Allergan's (AGN) sNDA for Vraylar gets the FDA approval for the treatment of adult patients with major depressive episodes related to bipolar I disorder.
Alaska Air (ALK) Up 2.4% Since Last Earnings Report: Can It Continue? http://www.zacks.com/stock/news/419541/alaska-air-alk-up-24-since-last-earnings-report-can-it-continue?cid=CS-ZC-FT-419541 May 25, 2019 - Alaska Air (ALK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ALXN or ALKS: Which Is the Better Value Stock Right Now? http://www.zacks.com/stock/news/415103/alxn-or-alks-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-415103 May 16, 2019 - ALXN vs. ALKS: Which Stock Is the Better Value Option?

Pages: 123456...25

Page 1>